瑞银:下调Iovance Biotherapeutics(IOVA.US)评级,由买入调整至中性评级,目标价由17.00美元调整至2.00美元。Iovance Biotherapeutics(IOVA.US)公司简介:Iovance Biotherapeutics Inc是一家临床阶段的生物制药公司,通过利用人体免疫系统识别和摧毁多种癌细胞的能力,为每位患者提供个性化治疗,开创了治疗癌症的变革性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.